Navigation Links
NBTY Acquisition of Julian Graves Unconditionally Cleared
Date:7/22/2009

RONKONKOMA, N.Y., July 22 /PRNewswire-FirstCall/ -- NBTY, Inc. (NYSE: NTY) (www.NBTY.com), a leading global manufacturer and marketer of nutritional supplements, today announced that its acquisition of Julian Graves has been unconditionally cleared in the United Kingdom by the provisional findings of the Competition Commission. The Competition Commission is expected to make its final decision on or before September 3, 2009.

NBTY's subsidiary, NBTY Europe, purchased Julian Graves, a chain of 350 food and confectionary stores in the U.K., on September 16, 2008, for approximately $25 million USD.

ABOUT NBTY

NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company's Nature's Bounty(R) (www.NaturesBounty.com), Vitamin World(R) www.VitaminWorld.com), Puritan's Pride(R) (www.Puritan.com), Holland & Barrett(R) (www.HollandAndBarrett.com), Rexall(R) (www.Rexall.com), Sundown(R) (www.SundownNutrition.com), MET-Rx(R) (www.MetRX.com), Worldwide Sport Nutrition(R) (www.SportNutrition.com), American Health(R) (www.AmericanHealthUS.com), GNC (UK)(R) (www.GNC.co.uk), DeTuinen(R) (www.DeTuinen.nl), LeNaturiste(TM) (www.LeNaturiste.com), SISU(R) (www.SISU.com), Solgar(R) (www.Solgar.com), Good 'n' Natural(R) (www.goodnnatural.com), Home Health(TM) (www.homehealthus.com), Julian Graves, and Ester-C(R) (www.Ester-C.com) brands. NBTY routinely posts information that may be important to investors on its web site.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of these forward looking statements are believed to be reasonable, they are inherently uncertain. Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and/or unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance and/or the costs of the same; (xiv) exposure to and expense of defending and resolving product liability and intellectual property claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes-Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

Consequently, such forward-looking statements should be regarded solely as NBTY's current plans, estimates and beliefs.

    Contact:  Harvey Kamil                               Carl Hymans
              NBTY, Inc.                                 G.S. Schwartz & Co.
              President & Chief Financial Officer        212-725-4500
              631-200-2020                               carlh@schwartz.com

'/>"/>
SOURCE NBTY, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
2. Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management
3. iMedX Announces Acquisition of Medware Inc.
4. SecureWorks Closes Acquisition of VeriSigns Managed Security Services Business
5. Triple-S Management Corporation Completes Acquisition of La Cruz Azul de Puerto Rico, Inc.
6. Gentiva(R) Health Services Acquisition Extends Certificate-of-Need Coverage in West Virginia
7. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
8. NeuroTherm Completes Acquisition of the Micron Epidural Catheter
9. Express Scripts Launches Senior Notes Offering to Finance Acquisition
10. Express Scripts Launches Equity Offering to Finance Acquisition
11. Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoints NextRx Subsidiaries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... San Ramon, CA (PRWEB) , ... February 23, 2017 , ... ... Kaplan, MD, FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and ... served as the chairman and CEO of the Virginia Mason Health System in Seattle ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leverages advanced data analytics to accurately understand each Medicare Advantage member’s risk, ... a given population. This new solution helps transform the HCC Risk Adjustment ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National Nutrition ... addition, the Company is helping people live healthier ... customized prescription savings programs in all 50 states ... Assistance Program  and  California Prescription Assistance Program . ... Columbia University for nutritious eating habits: ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... Korea , Feb. 23, 2017 LG Innotek today ... LED for sterilization applications. As its sterilization performance is 1.5 times ... the short wavelength ultraviolet rays in the range of 200 -- 280nm, ... proliferation of bacteria by destroying their DNA. LG Innotek,s product emits ... ...
Breaking Medicine Technology: